

Please amend the application as follows:

IN THE SPECIFICATION

Applicants have attached appendix A which is a clean copy of specification page 21. Applicants request that this page be substituted for former page 21. New page 21 has been amended at line 17 to recite "Table 1" instead of "Table 2". Applicants have also attached Appendix B which presents the amendment on page 21 in the bracket and underline form.

IN THE CLAIMS¹

- B¹
1. (Twice amended) An injectable, non-tumorigenic, human retinal pigment epithelial cell line, wherein the cell line is selected from the group consisting of hRPE-7, hRPE-116 and ARPE-19 and wherein the cells of the cell line:
 - (a) comprise an expression vector comprising a polynucleotide coding for a polypeptide selected from the group consisting of BDNF, NT-4, CNTF, Axokine, IGF I, IGF II, TGF β -II, Midkine, IL-1 β , TNF, NGF, IL-2/3, ILF, IL-6, NTN, Neublastin, VEGF, GDNF, PDGF, LEDGF and PEDF; and
 - (b) can non-tumorigenically interact with retinal cells of a mammalian host.
-
- B²
10. (Twice amended) The cell line according to claim 1, wherein the cell line is human retinal pigment epithelial-7 (hRPE-7) or human retinal pigment epithelial-116 (hRPE-116).

¹ Applicants have attached a copy of the claim amendments in bracket and underline form as Appendix C.